Under the agreement, Laureate will produce Tolerx’s humanized anti-GITR antibody known as TRX518, which is currently in development for cancer and chronic viral indications.
Robert Broeze, president and CEO of Laureate, said: “The partnership with Tolerx validates the progress we have made in biomanufacturing and our commitment in helping our clients bring novel therapies to the market. With our monoclonal antibody experience, we will partner closely with the Tolerx team to help them achieve their manufacturing objectives.”